|Positive IHC detected in||human thyroid cancer tissue, human lymphoma tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
14879-1-AP targets BTG1 in WB, IHC, IF, ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||HUMAN, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||BTG1 fusion protein Ag6651|
|Full Name||B-cell translocation gene 1, anti-proliferative|
|Calculated molecular weight||19 kDa|
|GenBank accession number||BC064953|
|Gene ID (NCBI)||694|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
BTG1 is a member of the TOB/BTG family of proteins known to inhibit cell proliferation and negatively regulate the cell cycle (PMID: 25017022). It is strongly expressed in quiescent cells (maximal in the G0/G1 phase) and down-regulated as the cells enter the growth cycle (PMID: 1373383). BTG1 protein is localized in cytoplasm and nucleus, and can interact with CAF1 and PRMT1 (PMID: 1113675, 9712883, 26622543). The aberration of BTG1 expression is associated with B-cell lymphocytic leukemia, and may serve as a diagnostic indicator and prognostic marker of thyroid carcinoma (PMID: 2069907, 25017022).
miR-27a-3p regulates proliferation and apoptosis of colon cancer cells by potentially targeting BTG1.
Int J Mol Med
B cell translocation gene 1 reduces the biological outcome of kidney cancer through induction of cell proliferation, cell cycle arrest, cell apoptosis and cell metastasis.
J Cell Physiol
Long noncoding RNA DGCR5 suppresses gastric cancer progression by acting as a competing endogenous RNA of PTEN and BTG1.
Int J Mol Sci
BTG1 expression correlates with the pathogenesis and progression of ovarian carcinomas.
BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy.